about
Use of romiplostim for primary immune thrombocytopenia in children.Smart pump alerts: all that glitters is not gold.Developing a drug library for smart pumps in a pediatric intensive care unit.Impact of implementing smart infusion pumps in a pediatric intensive care unit.Implementing smart pump technology in a pediatric intensive care unit: a cost-effective approach.Risks in the implementation and use of smart pumps in a pediatric intensive care unit: application of the failure mode and effects analysis.Safe intravenous administration in pediatrics: A 5-year Pediatric Intensive Care Unit experience with smart pumps.Pharmacotherapeutic review and update of idiopathic nephrotic syndrome in children.Development of a compatibility chart for intravenous Y-site drug administration in a pediatric intensive care unit.Preparation of intravenous drug administration guidelines for a pediatric intensive care unit.Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.Prevention and treatment of intraluminal catheter thrombosis in children hospitalised in a paediatric intensive care unit.Downbeat nystagmus due to ranitidine in a pediatric patient.[Subcutaneous ivermectin in disseminated strongyloidiasis: A veterinary preparation authorised for human use].Validation of a method for recording pharmaceutical interventions.[Off-label and unlicensed drug use: Results from a pilot study in a pediatric intensive care unit].[Paediatric training for developing clinical activities][Smart infusion pumps: lights and shadows of an emerging technology]Prescribing errors intercepted by clinical pharmacists in paediatrics and obstetrics in a tertiary hospital in SpainImplementation of smart pump technology in a paediatric intensive care unit[Systemic cytomegalovirus infection: changes in serum calcium and magnesium levels with foscarnet treatment]
P50
Q33399983-0E45CF5C-4565-4E55-8DB5-2AA94DDFE1D6Q34073076-DB52F5ED-BDBE-4E84-8DB7-CCDDB5AF4490Q34120894-CCDB1DE1-1936-4C89-9006-3C216944B8B4Q35017807-68D9B542-490D-4A34-9587-7D9810EBD1A0Q35057634-8A47E273-7009-4E9C-9153-587FCF059740Q35158711-C12CEEC8-799A-4050-93C0-9012E33B2811Q35973320-F3446723-386A-4445-AB1F-45087973ADACQ37709168-7D09381D-93E2-43AB-A577-0B96C1E3D9E7Q37989848-2392AFB5-2EF4-42C0-8250-CD2F6633A352Q38175318-7D42C1D1-439B-4D4D-942A-2B7F2552784CQ40611673-DEA4E715-8D6F-444D-9642-390CAD1CD0C8Q44295998-71C534D5-0574-442A-AA6D-652AB7404EFFQ47832072-120BCFE0-EFDE-401E-AA3E-B4EDBF8C72E3Q52840142-6341F575-7054-4F99-B5AF-5817A2600C9FQ53093635-ECEB1968-904E-4315-ACB6-9FF7699F3940Q53107573-E626076C-FF08-42EC-BF54-5E295C63E847Q82219399-247FC4CB-2B45-4C87-8CB5-7FE7090B5282Q83154105-F5E54710-CE1E-4603-A277-75A45265A27BQ83577730-3266EBC7-0781-4E9F-9C4A-1314AFAB3314Q87232074-A33F2F7C-728A-46F6-9D7B-3D34EB5F941BQ87789270-02BD4416-8715-4D5F-91B3-8775E840137D
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Silvia Manrique-Rodríguez
@ast
Silvia Manrique-Rodríguez
@en
Silvia Manrique-Rodríguez
@es
Silvia Manrique-Rodríguez
@nl
Silvia Manrique-Rodríguez
@sl
type
label
Silvia Manrique-Rodríguez
@ast
Silvia Manrique-Rodríguez
@en
Silvia Manrique-Rodríguez
@es
Silvia Manrique-Rodríguez
@nl
Silvia Manrique-Rodríguez
@sl
altLabel
Silvia Manrique-Rodríguez
@en
prefLabel
Silvia Manrique-Rodríguez
@ast
Silvia Manrique-Rodríguez
@en
Silvia Manrique-Rodríguez
@es
Silvia Manrique-Rodríguez
@nl
Silvia Manrique-Rodríguez
@sl
P1053
T-4741-2017
P106
P21
P2456
P31
P3829
P496
0000-0003-0238-7491